Andrew L Kau1, Phillip E Korenblat. 1. aDivision of Allergy and Immunology, Department of Internal Medicine, Washington University School of Medicine bClinical Research Center LLC, St. Louis, Missouri, USA.
Abstract
PURPOSE OF REVIEW: To summarize recent advances in IL-4 and IL-13 blockade in the treatment of asthma. RECENT FINDINGS: Historically, anticytokine therapies have historically been unsuccessful in the treatment of asthma because of the heterogeneity of its pathogenesis. Recent advances in our understanding of asthma pathophysiology and our increased ability to phenotype patients have led to the identification of asthmatic subsets (endotypes) that are most likely to respond to anticytokine therapy. Several new biologic therapies targeting IL-13 or both IL-4 and IL-13 signaling are currently in clinical trials and both types of therapies have demonstrated therapeutic benefit. SUMMARY: Anti-IL-4/13 therapies, guided by knowledge of an individual's underlying pathophysiology, are a promising class of therapies for treatment of asthma.
PURPOSE OF REVIEW: To summarize recent advances in IL-4 and IL-13 blockade in the treatment of asthma. RECENT FINDINGS: Historically, anticytokine therapies have historically been unsuccessful in the treatment of asthma because of the heterogeneity of its pathogenesis. Recent advances in our understanding of asthma pathophysiology and our increased ability to phenotype patients have led to the identification of asthmatic subsets (endotypes) that are most likely to respond to anticytokine therapy. Several new biologic therapies targeting IL-13 or both IL-4 and IL-13 signaling are currently in clinical trials and both types of therapies have demonstrated therapeutic benefit. SUMMARY: Anti-IL-4/13 therapies, guided by knowledge of an individual's underlying pathophysiology, are a promising class of therapies for treatment of asthma.
Authors: Rebecca E Slager; Gregory A Hawkins; Elizabeth J Ampleford; Alexandra Bowden; Lauren E Stevens; Matthew T Morton; Adrian Tomkinson; Sally E Wenzel; Malinda Longphre; Eugene R Bleecker; Deborah A Meyers Journal: J Allergy Clin Immunol Date: 2010-10 Impact factor: 10.793
Authors: Jan Lötvall; Cezmi A Akdis; Leonard B Bacharier; Leif Bjermer; Thomas B Casale; Adnan Custovic; Robert F Lemanske; Andrew J Wardlaw; Sally E Wenzel; Paul A Greenberger Journal: J Allergy Clin Immunol Date: 2011-02 Impact factor: 10.793
Authors: T K Hart; M N Blackburn; M Brigham-Burke; K Dede; N Al-Mahdi; P Zia-Amirhosseini; R M Cook Journal: Clin Exp Immunol Date: 2002-10 Impact factor: 4.330
Authors: Eric D Bateman; Homer A Boushey; Jean Bousquet; William W Busse; Tim J H Clark; Romain A Pauwels; Søren E Pedersen Journal: Am J Respir Crit Care Med Date: 2004-07-15 Impact factor: 21.405
Authors: Jonathan Corren; William Busse; Eli O Meltzer; Lyndon Mansfield; George Bensch; John Fahrenholz; Sally E Wenzel; Yun Chon; Meleana Dunn; Haoling H Weng; Shao-Lee Lin Journal: Am J Respir Crit Care Med Date: 2010-01-07 Impact factor: 21.405
Authors: Prescott G Woodruff; Homer A Boushey; Gregory M Dolganov; Chris S Barker; Yee Hwa Yang; Samantha Donnelly; Almut Ellwanger; Sukhvinder S Sidhu; Trang P Dao-Pick; Carlos Pantoja; David J Erle; Keith R Yamamoto; John V Fahy Journal: Proc Natl Acad Sci U S A Date: 2007-09-26 Impact factor: 11.205
Authors: Andrew Gallagher; Michaela Edwards; Parameswaran Nair; Stewart Drew; Aashish Vyas; Rashmi Sharma; Paul A Marsden; Ran Wang; David Jw Evans Journal: Cochrane Database Syst Rev Date: 2021-10-19
Authors: Catherine S Tripp; Carolyn Cuff; Andrew L Campbell; Barbara A Hendrickson; Jeff Voss; Terry Melim; Chengbin Wu; Andrew D Cherniack; Kenneth Kim Journal: Adv Ther Date: 2017-04-28 Impact factor: 3.845